LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met
UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19. The study met both its primary and secondary endpoints as well as demonstrated that a larger proportion of intermediate risk patients, which is the Liproca Depot target group, are PSA responders. The presentation can be accessed through LIDDS webpage and are also attached to this release.
The phase IIb results from the LPC-004 prostate cancer study was presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019 by Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients. Professor Klotz was one of the LPC-004 study investigators and is Professor at the University of Toronto Division of Urology at the Sunnybrook Health Sciences Centre in Canada.
The preliminary data recently released from the phase IIb study, LPC-004, confirms that 90 % of patients receiving 16 ml intraprostatic injection of Liproca® Depot experienced a PSA reduction and also that 16 ml is the optimal dosage for future Phase III studies. Further, the study showed no systemic hormonal adverse reactions, that Liproca® Depot is safe and well tolerated by the patients, and that 84 % of patients being treated were amenable to a second injection of Liproca® Depot.
As LIDDS advances Liproca® Depot towards late-stage clinical development, LIDDS intends to target intermediate risk patients in its phase III trial. The LPC-004 study showed that a larger proportion of intermediate risk patients are PSA responders and that this group display a stronger mean PSA decrease compared to low risk patients.
– The results confirm that Liproca® Depot can offer a completely novel approach to complement active surveillance in intermediate risk prostate cancer patients. Liproca® Depot is well tolerated without the hormonal side effects associated with anti-androgen therapy, and is equally easy to administer as performing a prostate biopsy. Liproca® Depot treatment could contribute to the benefit of prostate cancer patients in the future, says Professor Laurence Klotz, a world leading expert and one of the study investigators and Professor at the University of Toronto Division of Urology.
– The results regarding the intermediate risk patients further validate the continued clinical development of Liproca® Depot. As announced recently, our licensing partner, Jiangxi Phuong, has decided to progress with the phase III trial in China and we will continue the commercial activities in order to sign further licensing agreements in other major markets, says Monica Wallter, CEO, LIDDS.
About the Phase IIb Liproca® Depot clinical trial
The single blind, two-part dose finding study aimed to determine the highest tolerable dose of Liproca® Depot in part I and to determine the level of PSA reduction for part II patients at month 5. The study was conducted at eight specialist urology clinics in Canada; Lithuania and Finland. The study involved 61 patients diagnosed with localized non-aggressive prostate cancer who were on Active Surveillance. Patients were followed for six months to assess response and tolerability. Three previous clinical trials (LPC-001, LPC-002 and LPC-003) involved a total of 57 patients and showed promising results for tolerability and effect on tumor tissue, prostate volume and the PSA biomarker.
About prostate cancer and the market
Of the 1.2 million men diagnosed with prostate cancer globally each year, about 420,000 are assessed as intermediate risk and placed on ‘Active Surveillance’ where they are monitored regularly. There is no standard drug treatment for these cancer patients and many treating doctors see an unmet need.
According to market research firm GlobalData, the global market for prostate cancer drugs is expected to grow to USD 8.3 billion annually by 2023. Liproca® Depot’s target group is an untapped market potentially exceeding USD 3 billion per year.
About Liproca® Depot and NanoZolid®
NanoZolid® is a safe, flexible and functional method of delivering drugs. When injected, NanoZolid® forms a solid depot releasing the active drug over periods of potentially more than six months. As it releases its drug load, the NanoZolid® depot dissolves and is absorbed harmlessly into the body.
Liproca® Depot combines NanoZolid® and 2-HOF (2-hydroxyflutamide), a well-established antiprostate cancer drug. Liproca® Depot’s target group is patients under Active Surveillance (AS) with intermediate risk of cancer progression.
For additional information, please contact:
Monica Wallter, CEO, LIDDS +46 (0)737 07 09 22 email@example.com
This information is such that LIDDS AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, at 10:10 CET on November 16, 2019.
LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS (LIDDS) shares are listed on Nasdaq First North Growth Market. Redeye AB, firstname.lastname@example.org, +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit www.liddspharma.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Olainfarm invites to Third Quarter 2019 Investor Conference Webinar5.12.2019 18:17:00 CET | Press release
JSC Olainfarm invites shareholders, investors, mass media representatives and other stakeholders to join its investor conference webinar scheduled on December 11, 2019 at 16:00 (EET). To join the webinar please follow the instructions below. Webinar will be hosted by the Chairman of Management Board Jeroen Weites and Investor Relations Advisor Janis Dubrovskis. The presentation will be held in English. During the webinar JSC Olainfarm representatives will inform about the recent performance of the company and financial results of third quarter and 9 months of 2019. After the presentation investors are welcome to ask questions. Due to the limited webinar time please send in your questions in advance to e-mail: email@example.com. What is a webinar? Webinar is a virtual conference, during which company’s representative gives information about the company, its activities and future plans. Webinar allows interactive communication and provides an opportunity to ask questions and get answe
Auction details Inflation-linked bonds5.12.2019 16:20:00 CET | Press release
Auction date December 12, 2019 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2027-12-01 3113 SE0009548704 0.125% 500 Settlement date December 16, 2019 Bids have to be entered by 11.00 on December 12, 2019 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 firstname.lastname@example.org
Rockridge Receives Exploration Permit for its Raney Gold Project; Planning Drilling Program in Early 20205.12.2019 14:00:00 CET | Press release
VANCOUVER, British Columbia, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Rockridge Resources Ltd. (TSX-V: ROCK) (“Rockridge” or the “Company”) is pleased to announce that it has received an Exploration Permit for its Raney Gold Project located in Ontario, Canada (the “Raney Gold Project” or “Property”). The permit provides for exploration activities including geophysical surveys and diamond drilling to be conducted over a 3-year period. Highlights: Rockridge option to earn a 100% interest in the Raney Gold Project Prospective gold property located ~110 km south west of the prolific gold district of Timmins, ON Limited historical exploration campaigns conducted on the Property; the last exploration activities occurred ~10 years ago when gold prices were in the US$900/oz. range Follow-up on historical drill results, best intercept returned ~6.5 g/t gold over 8m, open for expansion Planning initial ~2,500 metre drilling program in February – April 2020; potential to discover additional gold bearing
Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notes5.12.2019 12:00:00 CET | Press release
Press release 5 December 2019 Svensk Hypotekspension Fond 3 AB (publ) – Early redemption of notes Svensk Hypotekspension Fond 3 AB (publ) (the “Issuer”) informs that it intends to voluntarily redeem the SEK 2,000,000,000 Mortgage Backed Fixed Rate Notes with ISIN SE0007691621 (the “Notes”) before the first call date in accordance with the terms and conditions originally dated 6 February 2016 and as amended and restated 27 November 2019 (the “Terms and Conditions”). All outstanding Notes will be redeemed in full at their nominal amount, together with accrued but unpaid interest and an early call premium. The redemption date is expected to be 17 December 2019 (the “Redemption Date”). A notice of early redemption will today be circulated to the holders of the Notes and will be published on the website of the Issuer. The notice will be irrevocable but conditional upon the Issuer’s receipt of satisfactory evidence that the Issuer’s affiliate Svensk Hypotekspension Fond 4 AB (publ)’s notes w
Svensk Hypotekspension Fond 3 AB (publ) – Tidig inlösen av obligation5.12.2019 12:00:00 CET | Pressemelding
Pressmeddelande den 5 december 2019 Svensk Hypotekspension Fond 3 AB (publ) – Tidig inlösen av obligation Svensk Hypotekspension Fond 3 AB (publ) (”Emittenten”) informerar att de avser att frivilligt lösa in de SEK 2 000 000 000 bolånesäkrade fastränteobligationerna med ISIN SE0007691621 (”Obligationerna”) före den första inlösendagen i enlighet med obligationsvillkoren, ursprungligen daterade den 6 februari 2016 och såsom ändrade och reviderade den 27 november 2019 (”Villkoren”). Samtliga utestående Obligationer kommer att lösas in till sitt nominella belopp, tillsammans med upplupen men obetald ränta och en premie för tidigt inlösen. Inlösendagen förväntas vara den 17 december 2019 (”Inlösendagen”). Ett meddelande om tidig inlösen kommer idag att cirkuleras till innehavare av Obligationerna och meddelandet kommer att publiceras på Emittentens hemsida. Meddelandet kommer att vara oåterkalleligt men villkorat av att Emittenten har tagit emot tillfredsställande bevis över att Emittenten
Nexstim Plc: Health Canada Grants Nexstim NBT® Medical Device License for Canada5.12.2019 10:10:00 CET | Press release
Company announcement, Helsinki, 5 December 2019 at 11.10 am (EET) Nexstim Plc: Health Canada Grants Nexstim NBT® Medical Device License for Canada Nexstim Plc (NXTMH:HEX, NXTMS:STO) announces that its NBT® System with SmartFocus® TMS technology has received a medical device license from Health Canada. The medical device license allows Nexstim to start marketing and commercial distribution of the NBT® system for the treatment of Major Depressive Disorder (MDD) in Canada. MDD is a recurrent and frequently chronic disorder with significant unmet clinical need: An estimated 10 per cent of Canadians use health services for mood and anxiety disorders annually1). According to Statistics Canada, 1,330,510 Canadians over the age of 15 reported indicators for ‘Major depression episode’ in 2012.2) Stimulation of the brain through Transcranial Magnetic Stimulation (TMS) has been demonstrated to be effective in the treatment of MDD in patients who have failed pharmacologic treatment.3) Nexstim has